Trinity Biotech plc (NASDAQ:TRIB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. “
Trinity Biotech plc (NASDAQ:TRIB) opened at 12.68 on Thursday. Trinity Biotech plc has a 12-month low of $9.20 and a 12-month high of $13.68. The company has a market capitalization of $291.84 million, a P/E ratio of 53.96 and a beta of 0.92. The company’s 50 day moving average price is $12.81 and its 200-day moving average price is $11.76.
Trinity Biotech plc (NASDAQ:TRIB) last released its quarterly earnings results on Thursday, July 21st. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. The company earned $26.30 million during the quarter, compared to the consensus estimate of $24.30 million. Equities analysts forecast that Trinity Biotech plc will post $0.14 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can bought a new stake in Trinity Biotech plc during the second quarter worth approximately $8,242,000. Emerald Acquisition Ltd. bought a new stake in Trinity Biotech plc during the second quarter worth approximately $5,109,000. Paradice Investment Management LLC raised its stake in Trinity Biotech plc by 13.3% in the second quarter. Paradice Investment Management LLC now owns 1,626,496 shares of the company’s stock worth $18,444,000 after buying an additional 190,772 shares during the period. Royce & Associates LP raised its stake in Trinity Biotech plc by 13.7% in the first quarter. Royce & Associates LP now owns 799,098 shares of the company’s stock worth $9,317,000 after buying an additional 96,500 shares during the period. Finally, US Bancorp DE raised its stake in Trinity Biotech plc by 7.6% in the second quarter. US Bancorp DE now owns 350,070 shares of the company’s stock worth $3,970,000 after buying an additional 24,857 shares during the period.
About Trinity Biotech plc
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trinity Biotech plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech plc and related companies with MarketBeat.com's FREE daily email newsletter.